A Study of IMC-1 In Patients With Fibromyalgia
CompletedPhase 2NCT01850420
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This is a randomized, double-blind, placebo-controlled, 16-week study designed to evaluate the hypothesis that tissue-resident herpes virus may be causally related to fibromyalgia symptoms or recurrence. IMC-1 is a combination treatment that is designed to suppress this suspected virus and thus alleviate fibromyalgia symptoms.
Study details
- Official title
- A Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of IMC-1 for the Treatment of Patients With Fibromyalgia
- Conditions
- Fibromyalgia
- Chronic Pain
- Myofascial Pain
- Interventions
- Drug: IMC-1
- Sponsor
- Innovative Med Concepts, LLC
- Start date
- 2013-05
- Primary completion
- 2014-01
- Sex
- All
- Age range
- from 18 Years to 70 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 12
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Diagnosis of fibromyalgia * English speaker Exclusion Criteria: * Rheumatologic diseases * Bipolar disease, OCD, severe anxiety, schizophrenia * Systemic infection, severe cardiac disease, chronic steroid usage * chronic opioid usage
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01850420